EGFR and non-small cell lung carcinoma: Liquid biopsy for detecting plasma circulating tumor DNA (ctDNA) has entered clinical practice in NSCLC for detection of EGFR mutations either at baseline in patients with no available tissue for tumor genotyping or at disease progression after 1st/2nd generation EGFR TKIs [3,4].